Literature DB >> 8856696

The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis.

G L Wenk1, W Danysz, D D Roice.   

Abstract

Increased glutamate or acetylcholine receptor stimulation may interact with mitochondrial failure to increase the vulnerability of cholinergic neurons within the nucleus basalis. Understanding of the mechanisms that underlie this vulnerability may lead to a therapy to prevent the degeneration of these neurons in Alzheimer's disease. In the presence of a mitochondrial energy deficit, excess stimulation of N-methyl-D-aspartate (NMDA) receptors was not required for cytotoxicity. Furthermore, stimulation of cholinergic receptors was cytotoxic to cholinergic neurons but this toxicity was not enhanced by NMDA stimulation. Chronic administration of NMDA antagonists, such as memantine, amantadine or MK-801, attenuated the effects of mitochondrial failure in the presence or absence of excessive cholinergic or NMDA receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8856696     DOI: 10.1097/00001756-199606170-00001

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  9 in total

1.  Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study.

Authors:  M B Hesselink; B G De Boer; D D Breimer; W Danysz
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

2.  Neuroprotective potential of ionotropic glutamate receptor antagonists.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

Review 3.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain.

Authors:  Catherine E Creeley; David F Wozniak; Anthony Nardi; Nuri B Farber; John W Olney
Journal:  Neurobiol Aging       Date:  2006-11-16       Impact factor: 4.673

5.  Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action.

Authors:  W Danysz; C G Parsons; H J Mobius; A Stoffler; G Quack
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 6.  Alzheimer disease.

Authors:  Rudy J Castellani; Raj K Rolston; Mark A Smith
Journal:  Dis Mon       Date:  2010-09       Impact factor: 3.800

7.  Chronic memantine does not block 3-nitropropionic acid-delayed ischaemic tolerance in rat hippocampal slices ex vivo.

Authors:  Tadeusz Frankiewicz; Chris G Parsons
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

8.  Neuroprotective effects of memantine in a mouse model of retinal degeneration induced by rotenone.

Authors:  Julio C Rojas; Jose A Saavedra; F Gonzalez-Lima
Journal:  Brain Res       Date:  2008-04-12       Impact factor: 3.252

Review 9.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.